Trace elements and electrolytes homeostasis and their relation to antioxidant enzyme activity in brain hyperexcitability of epileptic patients

Journal of Pharmacological Sciences

Volumn 96, Issue 4, 2004, Pages 349-359

  Hamed, Sherifa A ^a   Abdellah, Moustafa M ^a  

^a ASSIUT UNIVERSITY   (Egypt)

Author keywords

Antiepileptic drug; Antioxidant; Lipid peroxidation; Neuronal excitotoxicity; Trace element

Indexed keywords

ANTICONVULSIVE AGENT; ANTIOXIDANT; CARBAMAZEPINE; COPPER; ELECTROLYTE; FREE RADICAL; MEMBRANE LIPID; PHENYTOIN; SELENIUM; TRACE ELEMENT; VALPROIC ACID; ZINC;

BLOOD BRAIN BARRIER; BLOOD CEREBROSPINAL FLUID BARRIER; BRAIN DEPTH STIMULATION; BRAIN FUNCTION; ENZYME ACTIVITY; EPILEPSY; EPILEPTOGENESIS; HUMAN; LIPID PEROXIDATION; NERVE EXCITABILITY; NEUROPROTECTION; PATHOPHYSIOLOGY; REVIEW; RISK BENEFIT ANALYSIS;

EID: 12444255208     PISSN: 13478613     EISSN: None     Source Type: Journal    
DOI: 10.1254/jphs.CRJ04004X     Document Type: Review

References (136)

1. American Medical Association. The American Medical Association's/ Encyclopedia of medicine. Charles B, editor, Clayman: Random House; 1989. p. 396, p. 605, p. 752.
2. Takeda A. Zinc homeostasis and functions of zinc in the brain. Biometals. 2001;14:341-351.
3. Donaldson J, Cloutier T, Minnich JL, Barbeau A. Trace metals and biogenic amines in rat brain. Adv Neurol. 1974;5:245-252.
4. +-ATPaSe. Can J Biochem. 1971;49:1217-1224.
5. Wallwork JC. Zinc and the central nervous system. Prog Food Nutr Sci. 1987;11:203-247.
6. Itoh M, Ebadi M. The selective inhibition of hippocampal glutamic acid decarboxylase in zinc-induced epileptic seizures. Neurochem Res. 1982;7:1287-1288.
7. Smith WG, Bone I. Copper, zinc and magnesium plasma levels in epilepsy. J Neurol Neurosurg Psychiatry. 1982;45:1072.
8. Westbrook GL, Mayer ML. Micromolar concentrations of Zn antagonize NMDA and GABA response of hippocampal neurons. Nature. 1987;328:640-643.
9. Frederickson CJ, Moncrieff DW. Zinc-containing neurons. Biol Signals. 1994;3:127-139.
10. Barbeau A, Donaldson J. Zin, taurine and epilepsy. Arch Neurol. 1974;30:52-58.
11. Hunt DM. Copper and neurological function. Chiba Found Symp. 1980;79:247-266.
12. McCord EM, Weswig PH. Some selenium responses in the rat not related to vitamin E. J Nutr. 1969;98:383-389.
13. Rotruck JT, Pope AI, Ganther HE, Swanson AB, Hafeman DG, Hoekstra WG. Selenium: biochemical role as a component of glutathione peroxidase. Science. 1973;179:588-590.
14. Prasad AS. Clinical, biochemical, and pharmacological role of zinc. Ann Rev Pharmacol Toxicol. 1979;20:393-426.
15. Pfeiffer CC, Bravemann ER. Zinc, the brain and behavior. Biol Psychiatry. 1982;17:513-532.
16. Savaskan NE, Brauer AU, Kuhbacher M, Eyupoglu IY, Kyriakopoulos A, Ninnemann O, et al. Selenium deficiency increases susceptibility to glutamate-induced excitotoxicity. FASEB J. 2003;17:112-114.
17. Hirate M, Takeda A, Tamano H, Enomoto S, Oku N. Distribution of trace elements in the brain of EL (epilepsy) mice. Epilepsy Res. 2002;51:109-116.
18. Lerman-Sagie T, Statter M, Szabo G, Lerman P. Effect of valproic acid therapy on zinc metabolism in children with primary epilepsy. Clin Neuropharmacol. 1987;10:80-86.
19. Kuzuya T, Hasegawa T, Shimizu K, Nebeshima T. Effect of antiepileptic drugs on serum zinc, copper concentrations in epileptic patients. Int J Clin Pharmacol Ther Toxicol. 1993; 31:61-65.
20. Verrotti A, Basciani F, Trotta D, Pomilio MP, Morgese G, Chiare F. Serum copper, zinc, selenium, glutathione peroxidase and superoxide dismutase levels in epileptic children before and after 1 year of sodium valproate and carbamazepine therapy. Epilepsy Res. 2002;48:71-75.
21. Abbott LC, Nejad HH, Bottje WG, Hassan AS. Glutathione levels in specific brain regions of genetically epileptic (tg/tg) mice. Brain Res Bull. 1990;52:629-631.
22. Niketic V, Ristic S, Saicic ZS, Spasic M, Buzadzic B, Stojkovic M. Activities of antioxidant enzymes and formation of the glutathione adduct of hemoglobin (Hb ASSG) in epileptic patients with long-term antiepileptic therapy. Farmaco. 1995;50: 811-813.
23. Yüksel A, Cengiz M, Seven M, Ulutin T. Erythrocyte glutathione, glutathione peroxidase, superoxide dismutase and serum lipid peroxidation in epileptic children with valproate and carbamzepine monotherapy. J Basic Clin Pharmacol. 2000; 11:73-81.
24. Palm R, Hallmans G. Zinc and copper metabolism in phenytoin therapy. Epilepsia. 1982;23:453-461.
25. Ghose K, Taylor A. Hypercupraemia induced by antiepileptic drugs. Hum Toxicol. 1983;3:519-529.
26. Werther CA, Clud H, Ohtake M, Tamura T. Effects of long-term administration of anticonvulsants on copper, zinc and ceruloplasmin levels. Drug Nutr Interact. 1986;4:269-274.
27. Davidson SLW, Ward NI. Abnormal aluminium, cobalt, manganese, stronatium and zinc concentrations in untreated epilepsy. Epilepsy Res. 1988;1:3-13.
28. Rude RK. Physiology of Magnesium metabolism and the important role of magnesium in potassium deficiency. Am J Cardiol. 1989;63:31G-34G.
29. Kaji M, Ito M, Okuno T, Momoi T, Sasaki H, Yamanaka C, et al. Serum copper and zinc levels in epileptic children with valproate. Epilepsia. 1992;33:555-557.
30. Ilhan A, Uz E, Kali S, Var A, Akyol O. Serum and hair trace element levels in patients with epilepsy and healthy subjects: does the antiepileptic therapy affect the element concentrations of hair? Eur J Neurol. 1999;6:705-709.
31. Frederickson CJ. Neurobiology of zinc-containing neurons. Int Rev Neurobiol. 1989;31:145-238.
32. Mayer ML, Vyklicky L Jr, Westbrook GL. Modulation of excitatory amino acid receptors by group IIB metal cations in cultured mouse hippocampal neurons. J Physiol (Lond). 1989; 415:329-350.
33. Huang EP. Metal ions and synaptic transmission: think zinc. Proc Natl Acad Sci USA. 1997;94:13386-13387.
34. Takeda A, Hanajima T, Ijiro H, Ishige A, Iizuka S, Okada S, et al. Release of zinc from the brain of E1 (epilepsy) mice during seizure induction. Brain Res. 1999;828:174-178.
35. +-ATPase in brain. Can J Biochem. 1972;50:888-896.
36. Ebadi M, Wilt S, Ramaley R, Swanson S, Mebus C. The role of zinc and zinc-binding proteins in regulation of glutamic acid decarboxylase in brain. In: Evangenopoulas AD, editor. Progress in clinical and biological research. Vol. 144, Part A, Chemical and biological aspects of vitamin B6 catalysis. New York: Alan R. Liss; 1984. p. 255-275.
37. Buhl EH, Otis TS, Mody I. Zinc-induced collapse of augmented inhibition by GABA in a temporal lobe epilepsy model. Science. 1996;271:369-373.
38. Koh JY, Choi DW. Zinc alters excitatory amino acid neurotoxicity on cortical neurons. J Neurosci. 1988;8:2164-2171.
39. Weiss JH, Sensi SL, Koh JY. Zn(2+): a novel ionic mediator of neuronal injury in brain disease. Trends Pharmacol Sci. 2000; 21:395-401.
40. 2+ entry produces oxidative neuronal necrosis in cortical cell cultures. Eur J Neurosci. 1999;11:327-334.
41. Burk RF, Lawrence RA, Lane JM. Liver necrosis and lipid peroxidation in a rat as a result of paraquat and diquat administration: effect of selenium deficiency. J Clin Invest. 1980; 65:1024-1031.
42. Turan B, Dalay N, Afrasyap L, Delilbasi E, Sengun Z, Sayal A, et al. The effect of selenium supplementation on antioxidative enzyme activities and plasma and erythrocyte selenium levels. Acta Physiol Hung. 1993;81:87-93.
43. Ramaekers VT, Calomme M, Vanden Berghe D, Makropoulos W. Selenium deficiency triggering intractable seizures. Neuropediatrics. 1994;25:217-223.
44. Muth OH, Weswig PH, Whanger PD, Oldfield JE. Effect of feeding selenium-deficient ration to the subhuman primate. Am J Vet Res. 1971;32:1603-1605.
45. Subcommittee on Selenium, Committee on Animal Nutrition Agricultural Board, National Research Council. Selenium in nutrition. Washington: National Academy of Science; 1971. p. 4-20.
46. Magalova T, Beno I, Brtkova A, Mekinova D, Volkovova K, Staruchova M, et al. Levels of Cu, Zn, Se and their relation to levels of cerumloplasmin and the activity of antioxidative enzymes. Bratisl Lek Listy. 1997;98:8-11.
47. Halliwell B, Gulteridge JM. The antioxidants of human extracellular fluids. Arch Biochem Biophys. 1990;250:1-8.
48. Tsaryuk VV, Potapovich AI, Kostyuk VA. Protective effect of copper-rutin complex in animals with experimental epilepsy. Bull Exp Biol Med. 2002;133:334-335.
49. Willmore LJ, Rubin J. Antiperoxidant pretreatment and iron-induced epileptiform discharges in the rat: EEG and histopathologic studies. Neurology. 1981;31:63-69.
50. Kürekçi AE, Alpay F, Tanindi S, Gökçay E, Özcan O, Akin R, et al. Plasma trace element, plasma glutathione peroxidase, and superoxide dismutase levels in epileptic children receiving AEDs therapy. Epilepsia. 1995;36:600-604.
51. Maertens P, Dyken P, Graf E, Pippenger C, Chronister R, Shah A. Free radicals, anticonvulsants and the neuronal ceroidlipofuscinoeses. Am J Med Genet. 1995;57:225-228.
52. Gerber N, Dickinson RG, Harland RC, Lynn RK, Houghton LD, Antonias JI, et al. Reye-like syndrome associated with valproic acid therapy. J Pediatr. 1979;95:142-144.
53. Young RSK, Bergman I, Gang DL, Richardson EP. Fatal Reye-like syndrome associated with valproic acid. Ann Neurol. 1980;7:389.
54. Hurd RW, Van Rinsvelt HA, Wilder BJ, Karas B, Maenhaut W, DeReu L. Selenium, zinc and copper changes in valproic acid: possible correlation to drug side effects. Neurology. 1984; 34:1393-1395.
55. Jesberger JA, Richardson JS. Oxygen free radicals and brain dysfunction. Int J Neurosci. 1991;57:1-7.
56. Weber GF, Maertens P, Meng X, Pippenger CE. Glutathione peroxidase deficiency and childhood seizures. Lancet. 1991; 337:1443-1444.
57. Hall ED, Braughler JM. Central nervous system trauma and stroke. Physiological and pharmacological evidence for involvement of oxygen radicals and lipid peroxidation. Free Radic Biol Med. 1989;6:303-313.
58. Liu J, Mori A. Antioxidant and free radical scavenging activities of Gastrodia elata B1, and Uncoria rhynchophylla (Miq.) jacks. Neuropharmacology. 1992;31:1287-1298.
59. Holmes B, Park BH, Malawista SE, Quie PG, Nelson DL, Good RA. Chronic granulomatous disease in females. A deficiency of leukocytes glutathione peroxidase. N Engl J Med. 1970;283; 217-221.
60. Pippenger CE, Meng X, van Lente F. Alternative approaches to the prediction of antiepileptic idiosyncratic or drug-drug interactions. New York: Demos; 1989. p. 293-307.
61. Abdulla A, Ibse I. Utesluter normalt zinc serum zinkbrist? Lakartidningen. 1976;73:2104-2105. (text in Swedish with English abstract)
62. Evans GW. The role of copper in metabolic disorders. Adv Exp Med Biol. 1981;135:121-137.
63. Flanagan PR, Haist J, Valbery LS. Zinc absorption, intraluminal and intestinal metallothinein levls in zinc-deficient and zinc-replete rodents. J Nutri. 1983;237:335-339.
64. Akram M, Sullivan C, Mack G, Buchanan N. What is the clinical significance of reduced manganese and zinc levels n treated epileptic patients? Med J Aust. 1989;151:113-114.
65. Pippenger CE, Meng X, Von Lente F, Rothner AD. Valproate therapy suppresses GSH.PX and SOD enzyme activity. A possible mechanism for VPA induced idiosyncratic drug toxicity. Clin Chem. 1989;35:1173.
66. Sozuer DT, Barutcu UB, Karakoc Y, Yalcin E, Onen S. The effects of antiepileptic drugs on serum zinc and copper levels in children. J Basic Clin Physiol Pharmacol. 1995;6:265-269.
67. Tutor JC, Fernandez MP, Paz JM. Serum copper concentration and hepatic enzyme induction during long therapy with anticonvulsants. Clin Chem. 1982;28:1367-1370.
68. Taylor A, Ghose K. Diurnal variation of serum copper and zinc in epileptics receiving anticonvulsants. Hum Toxicol. 1986;5: 195-200.
69. Suzuki T, Koizumi J, Moroji T, Shiraishi H, Hori T, Baba A, et al. Effects of long-term anticonvulsants on copper, zinc and magnesium in hair and serum of epileptics. Biol Psychiatry. 1992;31:571-581.
70. Liu CS, Wu HM, Kao SH, Wei YH. Phenytoin-mediated oxidative stress in seum of female epileptics: a possible pathogenesis in fetal hydantoin syndrome. Hum Exp Toxicol. 1997;31:61-65.
71. Yuen WC, Whiteoak R, Thompson RP. Zinc concentrations in leucocytes of patients receiving antiepileptic drugs. J Clin Pathol. 1988;41:553-555.
72. Steidl L, Tolde I, Svomova V. Metabolism of magnesium and zinc in patients treated with antiepileptic drugs and with magnesium lactate. Magnesium. 1987;6:284-295.
73. Smith AJ, Hoorntje SJ, Donker AJM. Zinc deficiency during captopril treatment. Nephron. 1983;34:196-197.
74. Laker M. The uses of blood and hair on determining trace element levels in man. Lancet. 1982;31:260-262.
75. Manson P, Zlotkin S. Hair analysis - a critical review. Can Med Assoc J. 1985;133:186-188.
76. Dreier JP, Zhang C-L, Heinemann U. Phenytoin, phenobarbital, and midazolam fail to stop status epilepticus-like activity induced by low magnesium in rat entorhinal slices, but can prevent its development. Acta Neurol Scand. 1998;98:154-160.
77. Tange SM. Hair zinc and copper concentrations in patients with epilepsy. Zhonghua Shen Jing Shen Ke Za Zhi. 1991;24:94-97, 124-125. (abstract in Chinese)
78. Altunbasak S, Biatmakoui F, Baytok V, Herguner O, Burgt HR, Kayrin L. Serum and hair zinc levels in epileptic children taking valproic acid. Biol Trace Elem Res. 1997;58:117-125.
79. Agget PJ, Harries JT. Current status of zinc in health and disease states. Arch Dis Child. 1979;54:909-917.
80. Harris WR. Thermodynamic binding constants of the zinc-human serum transferrin complex. Biochemistry. 1983;22:3920-3926.
81. Ulvi H, Yigiter R, Yoldas T, Dolu Y, Var A, Müngen B. Magnesium, zinc, copper contents in hair and their serum concentrations in patients with epilepsy. East J Med. 2002;7:31-35.
82. Hurd RW, Wilder BJ, Street JJ, Sciscent BL. Zinc binding by valproic acid. Neuroscience Abstr. 1981;7:813.
83. Hamed SA, Abdellah MM, El-Melegy N. Blood levels of trace elements, electrolytes, and oxidative stress/antioxidant systems in epileptic patients. J Pharmacol Sci. 2004;96:465-473.
84. Lifschitz MD, Henkin RI. Circadian variation in copper and zinc in man. J App Physiol. 1971;31:88-92.
85. Rall TW, Schleifer LS. Drugs effective in the therapy of epilepsies. Goodman and Gilman's the pharmacological basis of therapeutics, 8th ed. Singapore: Pergamon Press, 1991. p. 436-462.
86. Shaw JCL. Trace elements in the fetus and young infant. Am J Dis Child. 1979;133:1260-1264.
87. Schott GD, Delves HT. Plasma zinc levels with anticonvuslant therapy. Br J Clin Pharmacol. 1978;5:279-280.
88. Hurd RW, Wilder BJ, Van Rinsvelt HA. Valproate, birth defects and zinc. Lancet. 1983;22:181.
89. Committee on Drugs (Pruitt AW, chairman). Valproic acid benefits and risks. Pediatrics. 1982;70:316-319.
90. Lenoir GR, Perignon JL, Gubler MC, Broyer M. Valproic acid: a possible cause of proximal tubule renal syndrome. J Pediatr. 1981;98:503-504.
91. Van Rinsvelt HA, Lear RD, Adams WR. Human diseases and trace elements. Investigation by proton induced x-ray emission. Nucl Inst Method. 1977;142:171-180.
92. Ozawa Y, Inagaki Y, Yonei Y, Tsukada N, Okawa H, Kiryu Y, et al. An adult case of Reye like syndrome and acute pancreatitis associated with sodium valproate. Nippon Shokakibyo Gakkai Zasshi. 1992;89:1467-1470. (text in Japanese with English abstrct)
93. Liu C, Wu H, Kao S, Wei Y. Serum trace elements, glutathione, copper/zinc superoxide dismutase, and lipid peroxidation in epileptic patients with phenytoin or carbamazepine monotherapy. Clin Neuropharmacol. 1998;21:62-64.
94. Shah QA, Jamil AA, Gupta VP, Kabiraj MM, Shah AH. Changes in serum electrolytes in childhood epilepsy: A hospital-based prospective. Greenwich J Sci Technol. 2001;2:18-27.
95. Fichsel H, Niewerth B, Schlehbusch H. Influence of antiepileptic drugs on copper and ceruloplasmin concentrations in epileptic children and juvenile in antiepileptic therapy. In: Oxley J, Janz D, Meinardi H, editors. Chronic toxicity of antiepileptic drugs. New York: Raven Press; 1983. p. 85-90.
96. Sherard ES, Steiman GS, Couri D. Treatment of childhood epilepsy with valproic acid: results of the first 100 patients in a six months trial. Neurology. 1980;30:31-35.
97. Wilder BJ, Bruni J. Seizure disorders: a pharmacological approach to treatment. New York: Raven Press; 1981. p. 83-96.
98. Solomons NW. Zink and copper in human nutrition. In: Selvey N, White PL, editors. Nutrition in the 1980's: constraints on our knowledge. New York: AL Liss; 1981. p. 97-127.
99. Jeavons P, Clark J, Harding G. Valproate and curly hair. Lancet. 1977;1:359.
100. Herranz JL, Arteaga R, Armijo JA. Change in hair color induced by valproic acid. Dev Med Child Neurol. 1981;23:386-387.
101. Millar MJ, Fischer MI, Elcoate PV, Mayson CA. The effects of dietary zinc deficiency on the reproductive system of male rats. Can J Biochem Physiol. 1958;36:557-569.
102. Brunia CHM, Buyze G. Serum copper levels and epilepsy. Epilepsia. 1972;13:621-625.
103. Motta E, Miller K, Ostrowska Z. Concentration of copper and ceruloplasmin in serum of patients treated for epilepsy. Wiad Lek. 1998;51:156-161. (text in Polish with English abstract).
104. Dakin KA, Weaver DF. Mechanism of post-traumatic seizures: a quantum pharmacological analysis of the molecular properties of an epileptogenic focus following iron-induced membrane peroxidation. Seizure. 1993;2:21-23.
105. Lindhout DH, Oppener RJ, Meinardi H. Teratogenicity of antiepileptic drug combinations with special emphasis on epoxidation (of carbamazepine). Epilepsia. 1984;25:77-83.
106. Sudha K, Rao AV, Rao A. Oxidative stress and antioxidants in epilepsy. Clin Chem Acta. 2001;303:19-24.
107. Martinez-Ballesteros C, Pita-Calandre E, Sanchez-Gonzalez Y, Rodriguez-Lopez CM, Agil A. Lipid peroxidation in adult patients treated with valproic acid. Rev Neurol. 2004;38:101-106. (text in Spanish with English abstract)
108. Graf WD, Oleinik OE, Glauser TA, Maertens P, Eder DN, Pippenger CE. Altered antioxidant activities in children with a serious side adverse experience related to valproic acid therapy. Neuropediatrics. 1998;29:195-201.
109. Rettie AE, Rettenmeier AW, Howald MN, Baillie TA. Cytochrome P450 catalyzed fromation of 4-VPA, a toxic metabolite of valproic acid. Science. 1987;235:890-893.
110. Rettenmeier AW, Prickett KS, Gordon PW, Bjorge SM, Change SL, Levy RH, et al. Studies on the biotransformatin in the perfused rat liver of 2-n-propyl-4pentenoic acid, a metabolic of the antiepileptic drug valproic acid. Evidence for the formation of chemically reactive intermediates. Drug Metab Dispos. 1985;13:81-96.
111. Cotariu D, Evans S, Zaidman JL, Marcus O. Early changes in hepatic redox homeostasis following treatment with a single dose of valproic acid. Biochem Pharmacol. 1990;40:589-593.
112. Rettie AE, Boberg M, Rettenmeier AW, Ballie TA. Cytochrome P450-catalyzed desaturation of valproic acid in vitro. Species differences, induction effects, and mechanistic studies. J Biol Chem. 1988;263:13733-13738.
113. Porubek DJ, Grillo MP, Baillie TA. The covalent binding to protein of valproic acid and its hepatotoxic metabolite, 2-n-propyl-4-pentenoic acid, in rats and in isolated rat hepatoctyes. Drug Metab Dispos. 1989;17:123-130.
114. Guengerich PF, Liebler DC. Enzymatic activation of chemicals to toxic metabolites. CRC Crit Rev Toxicol. 1985;14:259-307.
115. Roy D, Snodgrass WR. Covalent binding of phenytoin to protein and modulation of diphenylhydantoin metabolism by thiols in A/J mouse liver microsomes. J Pharmacol Exp Ther. 1990; 252:895-900.
116. Eichelbaum M, Tomson T, Tybring G, Bertilsson L. Carbamazepine metabolism in man: induction and pharmacogenetic aspects. Clin Pharmacokinet. 1985;10:80-90.
117. Vida JA. Anticonvulsants. In: Balado D, editor. Principles of medical chemistry. Baltimore: Williams and Wilkins; 1985. p. 190-191.
118. Tutor-Crespo MJ, Hermida J, Tutor JC. Assessment of copper status in epileptic patients treated with anticonvulsant drugs by measuring specific oxidase activity of ceruloplasmin. Epilepsy Res. 2003;56:147-153.
119. Maesaka JK, Fishban S. Regulation of renal urate excretion: a critical review. Am J Kidney Dis. 1998;32:917-933.
120. Ames BN, Catheart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci USA. 1981;78:6858-6862.
121. Rude RK. Magnesium metabolism and deficiency. Endocrinol Metab Clin North Am. 1993;22:377-395.
122. Papierkowski A, Mroczkowska JA, Pawlowska KA, Pasternak K. Magnesium and zinc levels in blood serum and cerebrospinal fluid in children with febrile convulsions. Pol Merkuriusz Lek. 1999;6:138-140.
123. Roitg I, Jamard B, Constantin A, Cantagrel A, Mazieres B, Laroche M. Severe refractory hypocalcemia in patients with enteropathy: consider hypomagnesemia. Joint Bone Spine. 2004;71:252-253.
124. Kandel ER. Transmitter release. In: Principles of neuronal science. Kandel ER, Schwartz JH, Vessel TM, editors. New York: Elsevier; 1991. p. 194-212.
125. Lewis R, Sibai B. Recent advances in the management of preeclampsia. J Matern Fetal Med. 1997;6:6-15.
126. Musiolino R, DeDeomenico P, Marino D, Labet C, Serra S, Siluestri R, et al. Epilepsy associated with hypocalcemia: description of a family. Funct Neurol. 1992;7:215-222.
127. Nzeh DA, Erasmus RT, Aiyedun BA. Serum electrolytes and protein changes after intravenous injection of sodium and meglumine diatrizoate (Urograffin-370). Afr J Med Sci. 1994;23:35-37.
128. Kiviranta T, Tuomisto L, Airaksine EM. Osmolarity and electrolytes in cerebrospinal fluid and serum of febrile children with and without seizures. Eur J Pediatr. 1996;155:120-125.
129. Lynch BJ, Rust RS. Natural history and outcome of neonatal hypocalcemic and hypomagnesemic seizures. Pediatr Neurol. 1994;11:23-27.
130. Sheth DP. Hypocalcemic seizures in neonates. Am J Emerg Med. 1997;15:638-641.
131. Rutter N, Smales OR. Calcium, magnesium and glucose levels in blood and CSF of children with febrile convulsions. Arch Dis Child. 1976;5:141-143.
132. Leaver DD, Parkinson GB, Schneider KM. Neurological consequences of magnesium deficiency: correlations with epilepsy. Clin Exp Pharmacol Physiol. 1987;14:361-370.
133. Natelson S, Miletich DJ, Seals CF, Visintine DJ, Albrecht RF. Clinical biochemistry of epilepsy 1. Nature of the disease and a review of chemical findings in epilepsy. Clin Chem. 1979;25: 889-897.
134. Koivikko MJ, Valikangas SL. Hyponatraemia during carbamazepine therapy in children. Neuropediatrics. 1983;14:93-96.
135. Biochonski R. Electrochemical blood properties in epileptic children. Neurol Neurochir Pol. 1976;10:249-254.
136. White HS, Chow SY, Yen-Chow YC, Woodbury DM. Effect of elevated potassium on the ion content of mouse astrocytes and neurons. Can J Physiol Pharmacol. 1992;70 Suppl:S263-S268.